Stretching of the atrial wall is a known stimulant for atrial natriuretic peptide (ANP) secretion. Little is known about other factors that may influence ANP secretion. We examined the effects of the neurotransmitters of the autonomic nervous system on ANP secretion from isolated rat left atria. Superfusion with 10 pM norepinephrine produced a biphasic rise in ANP secretion with a peak response 2.5-fold above baseline secretion. To determine whether the response to norepinephrine primarily reflected a-or jl-adrenergic receptor stimulation, atria were superfused with 0.1 gM isoproterenol or 10 MtM phenylephrine and 1 MM propranolol. ANP secretion in response to isoproterenol was biphasic, similar to the response to norepinephrine. Phenylephrine evoked a monophasic ANP secretory response, which was delayed in onset relative to that of isoproterenol or norepinephrine. Superfusion with 10 ,M methacholine alone had no effect on ANP secretion, but rapidly attenuated norepinephrine-stimulated secretion by 67%.
Introduction logical role in protecting the organism from volume overload due to its potent natriuretic and diuretic properties (3-6). However, little is known about factors that may influence ANP secretion. Mechanical distension or stretching of the atrial wall may be the primary physiological stimulus for ANP secretion (1, (7) (8) (9) ; however, ANP secretion may be modulated by other factors. Since atrial tissue is richly innervated by both sympathetic and parasympathetic nerve fibers, it is possible that the neurotransmitters norepinephrine or acetylcholine may influence ANP secretion. In this study, we examined the effects of adrenergic and muscarinic cholinergic agonists on ANP secretion by isolated rat left atria paced and superfused in vitro.
Methods
Female Sprague-Dawley rats weighing 200-225 g on an ad lib. sodium diet were killed by decapitation. Hearts were quickly removed and allowed to beat for 1-2 min in medium 199 with modified Earle's salts (KCl, 4 .0 mM) gassed with 95% 02/5% CO2 to remove blood. Left atria were quickly removed, mounted, and superfused as previously described (10) . Resting tension was initially set at 1.25 g and was not adjusted further. Atria were electrically paced at a rate of 1 Hz for 30 min and then at 2 Hz, except in the isoproterenol experiments where atria were paced at 3 Hz. After the pacing frequency adjustment, the atria were allowed to stabilize for 55 min. Thereafter, samples were collected at 2.5 min intervals. The following concentrations ofagonists were used in these studies: 10 AM norepinephrine, 10 ,M methacholine, 0.1 MM isoproterenol, and 10 MM phenylephrine. These concentrations of agonists were chosen since they produce a maximal change in developed tension. 100 MM ascorbic acid was added to the medium 199 for all experiments to decrease oxidation of adrenergic agonists.
ANP secretion was quantitated by RIA as previously described (10) with the following changes. Rat a-ANP was labeled with 1251 by the chloramine T method. Purification of the labeled hormone was achieved by reverse-phase HPLC using a Bondapak CI8 column and a linear gradient from acetonitrile/water (1:12) to 100% acetonitrile. 121-ANP eluted at 65% acetonitrile.
The results are expressed as a percent ofbasal ANP secretion. Basal ANP secretion was defined as the mean ofseven samples collected over 15 min immediately before the introduction of adrenergic or muscarinic cholinergic agonists.
Results
Representative tracings, illustrating the contractile responses of atria exposed to adrenergic and muscarinic cholinergic agonists, are presented in Fig. 1 . Developed tension rose in response to the adrenergic agonists norepinephrine, isoproterenol, and phenylephrine and fell in response to the muscarinic cholinergic agonist methacholine. The contractile responses of atria exposed to these agents are summarized in Table I .
To examine the possibility that sympathetic or parasympa- (Fig. 2 A) . The ANP-IR secretory response to norepinephrine was inhibited by simultaneous superfusion with 10 ,M phentolamine and 5 AM propanolol (Fig. 2 A) . ANP-IR secretion was not affected by superfusion with 10 AM methacholine (Fig. 2 B) in spite of a marked fall in developed tension (Table I) .
Since norepinephrine possesses both a-and ,3-adrenergic agonist activity, experiments were designed to determine whether the ANP-IR secretory response to norepinephrine reflected an a-or fl-adrenergic effect. Continuous superfusion with the #3-adrenergic agonist isoproterenol (0.1 AM) resulted in a biphasic ANP secretory response (Fig. 3 A) tExperimenial measurements taken during superfusion with the test agent. §RT, Resting tension, mean±SE.
1DT, Developed tension (peak tension minus resting tension). P < 0.02 compared with basal measurements by paired t test. ** NC, No change. secretory response elicited for norepinephrine ( Fig. 2 A) . The stimulatory effect of isoproterenol was inhibited by simultaneous superfusion with i MM propranolol (Fig. 3 A) . The ANP-IR secretory response to a-adrenergic stimulation was examined by superfusing atria with 10 IM phenylephrine and 1 AM propranolol, since phenylephrine possesses a small amount of f3-adrenergic agonist activity. Continuous superfusion with phenylephrine and propranolol resulted in a motophasic rise in ANP-IR secretion that was inhibited by simultaneous superfusion with 10 MM phentolamine ( Fig. 3 B) . The ANP-IR secretory response to phenylephrine was distinct from that of norepinephrine and isoproterenol, which were similar (Fig. 4) . The secretory response to phenylephrine was less rapid in onset and did not produce the biphasic response typified by norepinephrine or isoproterenol stimulation. Thus, the pattern of the ANP secretory response to norepinephrine appeared to be similar to the fl-adrenergic agonist isoproterenol.
These observations raised the question whether the secretory response to norepinephrine was exclusively a $-adrenergic 5 A) similar to that noted for norepinephrine alone (Fig. 2 A) or isoproterenol (Fig. 3 A) . A response to norepinephrine superfused with propranolol was also present (Fig. 5 B) . The pattern ofthis response was similar to that seen for phenylephrine (Fig. 3 B) . Thus, both the a-and f-adrenergic agonist properties of norepinephrine are capable of stimulating ANP secretion. Therefore, it appears that the ANP secretory response to norepinephrine reflects a predominance of f3-adrenergic activity over that of an a-adrenergic effect.
In light of the observation that an a-adrenergic secretory response could be elicited by superfusion with norepinephrine and propranolol, the predominance of the ,3-adrenergic secretory pattern of norepinephrine was examined at a lower concentration of norepinephrine (0.25 ,M). This concentration of norepinephrine resulted in a half-maximal increase in developed tension, whereas the 10-MM dose gave a maximal rise in developed tension. Superfusion with 0.25 MAM norepinephrine continued to give a biphasic ANP secretory response pattern (Fig. 6) . Thus, the predominance of the f3-adrenergic secretory pattern of norepinephrine persists even at a lower concentration of norepinephrine. Next to be examined was the possibility of an interaction between sympathetic and parasympathetic neurotransmitters on ANP secretion. Atria were initially superfused with 10 ,uM norepinephrine followed by the addition of 10 MM methacholine (Fig. 7) . The results in this figure are expressed as the net percent change from baseline in ANP-IR secretion with the response at 45 or 47.5 min defined as 100%. Continuous superfusion with norepinephrine again resulted in a biphasic ANP-IR secretory response. The curve is less well defined in this experiment, since samples were collected every 5 min rather than every 2.5 min. Addition of methacholine continuously superfused from 45 to 75 min resulted in a dramatic fall in ANP-IR secretion to a nadir of 33±7% of the maximal response. Continuous superfusion with norepinephrine alone or addition of 10 MM methacholine in the presence of 10 gM atropine rendered ANP-IR secretion stable until the experiment was terminated. In these experiments, developed tension rose from 0.20±0.03 to 0.77±0.14 g with the addition of norepinephrine. Methacholine lowered developed tension to 0.19±0.05 g. Thus, methacholine failed to influence basal ANP-IR secretion (Fig. 2 B) , but markedly inhibited norepinephrine-stimulated ANP-IR secretion (Fig. 7) .
Discussion
Both a-and /3-adrenergic agonists stimulate ANP secretion by isolated, paced rat left atria. However, the pattern of the secretory response by each is unique. The a,-adrenergic agonist phenylephrine induces a monophasic rise in ANP secretion, whereas the f3-adrenergic agonist isoproterenol produces a biphasic pattern of release. Also, the rapidity of the initial ANP secretory response differs quantitatively for a-and (3-adrenergic stimuli. The initial secretory response to a-adrenergic stimulation is slower to develop relative to the fl-adrenergic response. The differences in the atrial responses to phenylephrine and isoproterenol are further exemplified by the disparity in the onset and rate of rise of developed tension (1 1, 12, and Norepinephrine, which possesses both a-and (3-adrenergic activity, stimulates ANP secretion. The pattern ofthe ANP-IR secretory response to norepinephrine was similar to that of isoproterenol and dissimilar to the response pattern elicited by phenylephrine. This is consistent with the dominant fl-adrenergic agonist effect of norepinephrine in cardiac tissues (11) .
However, norepinephrine also possesses the capability of stimulating ANP secretion by an a-adrenergic effect (Fig. 5 B) . These observations suggest that norepinephrine-stimulated ANP-IR secretion reflects a predominance of (-adrenergic activity.
The effect of norepinephrine on ANP secretion in vitro has been previously reported to produce no change using statically incubated rat atria (15) or to have a stimulatory effect on secretion by the perfused rat heart (16) . The secretory pattern of the norepinephrine-stimulated ANP response in the latter study was not thoroughly defined, since the time of perfusion with norepinephrine was not long enough to achieve a maximal response. In the present study, we were able to define the pattern of the secretory response to norepinephrine. Failure to observe an ANP secretory response to norepinephrine by Ar- jamaa and Vuolteenaho may be due to the inherent limitations in sensitivity using an incubation technique (15).
Epinephrine has been reported to stimulate ANP secretion in all (17, 18) but one study (15). The ANP secretory response to norepinephrine or epinephrine has been previously considered to be due to an a1-adrenergic effect (16, 18 Activation of the sympathetic nervous system or a fall in parasympathetic tone may enhance ANP secretion. This may be one of the mechanisms whereby exercise increases plasma ANP in man (22) (23) (24) . In contrast, a rise in activity of the parasympathetic nervous system may lower ANP secretion.
The autonomic nervous system may also modulate the ANP secretory response to other stimuli, such as stretch, by increasing the secretory response due to an increase in sympathetic tone and lowering the response due to an increase in parasympathetic tone. However, Ledsome and Methacholine does not influence basal ANP secretion but does inhibit norepinephrine-stimulated ANP secretion. Thus, the endogenous neurotransmitters of the autonomic nervous system norepinephrine and acetylcholine may influence ANP secretion in vivo by augmenting ANP secretion with an increase in sympathetic tone and lowering ANP secretion by elevating parasympathetic tone.
